*Sponsored

Krypton Street Announces Its Next Potential Breakout Idea!

See Why Tonix Pharmaceuticals (NASDAQ: TNXP) is Topping Our Early Watchlist This Morning—Wednesday April 8, 2025.

Tonix Pharmaceuticals (NASDAQ: TNXP) Comes Backed By Several

Potential Catalysts Including:

Analyst Coverage: (TNXP) Has Caught Analysts’ Attention, With One Placing A $50 Valuation (157% Upside Potential ) And Another Issuing A $70 Target

 (260% Upside Potential).

Low Float: After A Reverse Split, (TNXP) Now Has Under 6.5M Shares In Its Float And A Market Cap Under $140M, Indicating Potential For Significant Movements If Demand Begins To Shift.

Promising Product Pipeline: (TNXP) Is Developing Treatments For High-Need Conditions With Limited Options, Positioning The Company As A Leader In Underserved Markets.

Path To FDA Approval: With Key Regulatory Decisions Ahead, Including The FDA Review Of TNX-102 SL, (TNXP) Could See Its Treatments Approved And Ready For Market, Driving Future Growth.

Pull Up (TNXP) While It’s Still Early—Here’s Why…

April 9, 2025

Dear Reader,

This just landed on our radar—and it’s now topping our early watchlist this morning.

Tonix Pharmaceuticals (NASDAQ: TNXP) is a little-known pharmaceutical company that could soon make its own headlines.

Tonix is positioning itself at the forefront of addressing some of the most complex and underserved areas in healthcare.

While it may not yet be as widely recognized as some of its larger counterparts, (TNXP) is making remarkable strides in developing treatments for high-need conditions, including fibromyalgia, cocaine intoxication, and rare diseases like Prader-Willi Syndrome.

But here’s where things get interesting:

Two analysts have recently set significant targets for (TNXP), suggesting impressive upside potential.

Less than two weeks ago, Robert LeBoyer, Senior Vice President and Equity Research Analyst at Noble Capital Markets, issued a $70 target for (TNXP), suggesting 260% upside potential.

Here are some of the recent moves that have caught our attention:

03/12/2025: $12.99 → 03/24/2025: $37.83: Inside of 9 sessions – Approx. move 191%

03/05/2025: $8.10 → 03/06/2025: $18.63: Overnight – Approx. move 130%

03/21/2025: $18.36 → 03/24/2025: $37.83: Over the weekend – Approx. move 106%

03/04/2025: $6.76 → 03/05/2025: $11.70: Overnight – Approx. move 73%

03/20/2025: $16.64 → 03/21/2025: $23.98: Overnight – Approx. move 44%

In fact, after a recent reverse split earlier this week, Tonix Pharmaceuticals (NASDAQ: TNXP) now has just 6.5M shares in its float and a market cap under $140M.

With such a low float, (TNXP) has the potential to experience significant price swings if demand begins to shift, making it especially attractive to those who thrive on volatility.

When combined with its promising pipeline, Tonix Pharmaceuticals (NASDAQ: TNXP) could have a higher potential for growth compared to larger companies in the space.

Now let’s dive into why Tonix Pharmaceuticals (NASDAQ: TNXP) is topping our watchlist this morning.

Tonix Pharmaceuticals (NASDAQ: TNXP) is a company that has positioned itself at the forefront of addressing some of the most challenging and underserved areas of healthcare.

While the company may not be as widely recognized as some of its larger biotech counterparts, Tonix Pharmaceuticals (NASDAQ: TNXP) is making significant strides in developing treatments for conditions that impact a large number of people, including fibromyalgia, co-ca-ine intoxication, and rare diseases like Prader-Willi Syndrome.

A Focused Portfolio with High Unmet Needs

Here’s a look at some of their most promising candidates:

TNX-102 SL (Sublingual Cyclobenzaprine): This treatment is targeting fibromyalgia, a chronic pain disorder that significantly impacts the quality of life for many individuals.

What sets TNX-102 SL apart is its unique sublingual formulation, designed to be absorbed quickly into the bloodstream, bypassing the liver’s first-pass metabolism. This method could potentially reduce side effects commonly associated with traditional oral cyclobenzaprine formulations.

Given the limitations of current treatments for fibromyalgia, TNX-102 SL holds great promise for those suffering from this condition.

Status: The dr-ug is advancing rapidly through clinical trials. Tonix received FDA Fast Track Designation in 2024 and submitted its New Application (NDA) in October 2024.

With a Prescription User Fee Act (PDUFA) goal date set for August 15, 2025, the company is now awaiting regulatory approval.

TNX-1300 (Co-ca-ine Esterase): With this product, Tonix aims to address co-ca-ine intoxication by developing an enzyme-based treatment that neutralizes the dr-ug in the bloodstream.

Funded by the National Institute on Dr-ug Abuse (NIDA), TNX-1300 is a promising therapeutic option for an often-overlooked medical emergency.

TNX-2900 (Intranasal Potentiated Ox-yto-cin): Targeting Prader-Willi Syndrome, this investigational dr-ug could have a profound impact on a rare genetic disorder that causes severe hunger and developmental challenges.

The FDA has already granted Orphan and Rare Pediatric Disease Designations to TNX-2900, further underscoring its potential.

TNX-1500 (Anti-CD40L Monoclonal Antibody): Tonix is also exploring treatments for organ transplant rejection and autoimmune conditions.

TNX-1500 is designed to prevent the immune system from attacking transplanted organs, which could revolutionize the management of transplant recipients.

The Fibromyalgia Market: A Major Unmet Need

The existing therapies often come with significant side effects, and up to 85% of patients fail to find success with first-line treatments. This creates a significant need for a more effective solution.

TNX-102 SL, Tonix’s sublingual cyclobenzaprine, aims to address this gap by offering a treatment option that could target pain, sleep disturbances, and fatigue—the three hallmark symptoms of fibromyalgia—without the drawbacks of current therapies.

In their recent pivotal Phase 3 RESILIENT study, Tonix showed a statistically significant reduction in daily pain compared to a placebo, a result that could position TNX-102 SL as a breakthrough in the treatment of fibromyalgia.

The Science Behind TNX-102 SL: Innovative Delivery, Enhanced Efficacy

Why is Tonix so confident in TNX-102 SL?

The answer lies in its sublingual formulation, which allows the dr-ug to bypass the liver’s first-pass metabolism and enter the bloodstream more efficiently.

This results in faster absorption and potentially fewer side effects compared to oral treatments, which undergo metabolism in the liver and can generate persistent metabolites like norCBP that may cause unwanted side effects.

By leveraging a patent-protected eutectic formulation, Tonix has designed a product that promises to deliver the therapeutic effects of cyclobenzaprine more effectively, particularly for individuals who need a non-opioid analgesic.

This innovative approach could significantly improve treatment adherence and patient outcomes.

Looking Ahead: The Path Forward for Tonix Pharmaceuticals

Their pipeline of promising dr-ug candidates—backed by rigorous clinical trials and the support of government funding—positions them well for future success.

While the road to approval is never guaranteed, Tonix’s innovative approach to treating chronic conditions like fibromyalgia and rare diseases makes them a company worth watching.

With key regulatory milestones ahead, including the FDA’s decision on TNX-102 SL expected by August 2025, the coming months could prove pivotal for Tonix.

If their dr-ugs meet the rigorous standards of the FDA, Tonix Pharmaceuticals may very well become a leading player in the biotech space, offering new hope to patients in desperate need of better treatment options.

Recent Developments…

Positive Data for TNX-102 SL in Fibromyalgia

Tonix Pharmaceuticals (NASDAQ: TNXP) presented new data at the American Academy of Pain Medicine’s Annual Meeting in April 2025, showing promising effects of TNX-102 SL in treating fibromyalgia. The data highlighted the potential to reduce pain and improve sleep quality for those suffering from this challenging condition.

Launch of TONIX ONE Digital Platform

On April 1, 2025, Tonix Pharmaceuticals (NASDAQ: TNXP) launchedTONIX ONE, a comprehensive digital platform designed to help migraine patients better understand and manage their condition. This initiative aims to provide patients with personalized insights and recommendations, enhancing their ability to track and manage migraines.

FDA’s Decision on TNX-102 SL

On March 24, 2025, Tonix Pharmaceuticals (NASDAQ: TNXP)announced that the FDA will not require an advisory committee meeting to review its New Application (NDA) for TNX-102 SL, marking a significant step forward for the treatment of fibromyalgia. This news suggests that the company is on track to receive FDA approval in the near future.

Grant for TNX-801 Development

On March 10, 2025, Tonix Pharmaceuticals (NASDAQ: TNXP) secureda grant from the Medical CBRN Defense Consortium to advance the development of TNX-801, a single-dose therapeutic candidate for specific infectious diseases. The funding will support further development, including market analysis and planning for both private and government sectors.

7 Reasons Why Tonix Pharmaceuticals (NASDAQ: TNXP) is Topping Our Watchlist This Morning…

1. Analyst Coverage: (TNXP) has garnered attention from top analysts, with Zacks Small Cap Research analyst David Bautz, PhD, placing a $50 valuation on the company, suggesting a potential upside of 157% from yesterday’s open. Similarly, Robert LeBoyer, Senior Vice President at Noble Capital Markets, issued a $70 target, indicating a potential upside of 260%.

2. Low Float: After a reverse split, (TNXP) now has under 6.5M shares in its float and a market cap under $140M, suggesting potential for significant price movements if demand shifts.

3. Promising Product Pipeline: (TNXP) is developing treatments for high-need conditions with limited options, positioning the company as a leader in underserved markets.

4. Fast-Tracked Treatment for Fibromyalgia: (TNXP)’s TNX-102 SL is advancing rapidly through clinical trials for fibromyalgia, with FDA Fast Track Designation and a PDUFA goal date of August 15, 2025.

5. Innovative Approach to Delivery: TNX-102 SL uses a sublingual delivery method, bypassing the liver’s metabolism, offering faster absorption and fewer side effects compared to oral treatments.

6. Strategic Focus on Rare and Underserved Diseases: (TNXP) is targeting rare conditions like Prader-Willi Syndrome and co-ca-ine intoxication, positioning it for growth in low-competition markets.

7. Path to FDA Approval: With key regulatory decisions ahead, including the FDA review of TNX-102 SL, (TNXP) could see its treatments approved and ready for market, driving future growth.

Consider Adding Tonix Pharmaceuticals (NASDAQ: TNXP) To

Your Radar While It’s Still Early…

Tonix Pharmaceuticals (NASDAQ: TNXP) is a company to keep an eye on as it moves forward with a promising pipeline, a low float that could lead to significant swings, and FDA fast-track status for its treatments.

With a focus on rare, underserved diseases and strong government backing, Tonix is well-positioned to make strides in the healthcare space.

We have all eyes on (TNXP) this morning.

Consider taking a look at (TNXP) while it’s still early.

My next update should be out to you shortly—maybe even within the hour—keep an eye out for it.

Alex Ramsay

Co-Founder / Managing Editor

Krypton Street Newsletter

KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors.

The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media.

*Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 04/08/2025 and ending on 04/09/2025 to publicly disseminate information about (TNXP:US) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Media 1717 LLC has been paid twenty six thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC and their member own shares of (TNXP:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/tnxp/#details